Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Down 18.6% in December

Aspira Women’s Health Inc. (NASDAQ:AWH) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 356,900 shares, a decline of 18.6% from the December 15th total of 438,500 shares. Based on an average trading volume of 100,900 shares, the days-to-cover ratio is currently 3.5 days. Approximately 2.9% of the company’s shares are short sold.

Institutional Trading of Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co bought a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health as of its most recent filing with the SEC. 12.19% of the stock is currently owned by institutional investors and hedge funds.

Aspira Women’s Health Trading Down 3.1 %

Shares of NASDAQ AWH traded down $0.02 during mid-day trading on Friday, reaching $0.50. 65,362 shares of the company’s stock were exchanged, compared to its average volume of 78,759. Aspira Women’s Health has a twelve month low of $0.38 and a twelve month high of $5.65. The firm has a market capitalization of $8.34 million, a price-to-earnings ratio of -0.42 and a beta of 1.42. The business has a fifty day simple moving average of $0.74 and a 200 day simple moving average of $0.93.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Aspira Women’s Health in a research report on Sunday, January 12th. They set a “hold” rating on the stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.